Related Experiment Video

Updated: Jul 8, 2026

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update

Abraham Fisher1

  • 1Israel Institute for Biological Research, P.O.Box 19, 74100 Ness-Ziona, Israel. fisher_a@netvision.net.il

Current Alzheimer Research
|January 29, 2008
PubMed
Abstract

Insights

Selective M1 muscarinic agonists, like AF267B, show promise in treating Alzheimer's disease (AD) by targeting key pathologies. These compounds effectively reduced beta-amyloid and tau issues while improving cognitive function in AD models.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is characterized by cholinergic deficiency, cognitive decline, and beta-amyloid (Abeta) and tau pathologies.
  • The M1 muscarinic acetylcholine receptor (M1 mAChR) is a key target in AD, but previous agonists had limited clinical utility due to side effects and lack of selectivity.
  • Developing selective M1 mAChR agonists offers a potential therapeutic strategy for AD.

Purpose of the Study:

  • To evaluate the efficacy and safety of M1 selective muscarinic agonists, specifically AF102B, AF150(S), and AF267B, in preclinical models of Alzheimer's disease.
  • To investigate the molecular mechanisms underlying the therapeutic effects of these agonists on AD hallmarks.
  • To assess the potential of AF267B as a single-agent therapy for AD.

Main Methods:

  • In vitro studies using M1 mAChR modulation to assess effects on alphaAPPs, Abeta levels, tau hyperphosphorylation, and Abeta-induced neurotoxicity.
  • In vivo studies in relevant animal models to evaluate cognitive function, cholinergic markers, and tau pathology.
  • Pharmacokinetic and safety assessments in various animal models, including rabbits and transgenic AD mice.
  • Analysis of molecular targets including PKC, MAPK, GSK3beta, ADAM17/TACE, and BACE1.

Main Results:

  • M1 selective agonists (AF102B, AF150(S), AF267B) reduced Abeta levels and tau hyperphosphorylation in vitro via M1 mAChR-mediated kinase modulation.
  • These agonists restored cognitive deficits and improved cholinergic markers in AD models with a good safety margin.
  • AF267B demonstrated significant reduction of brain and CSF Abeta levels and vascular Abeta deposition in rabbits.
  • Chronic AF267B treatment in 3x transgenic-AD mice rescued cognitive deficits and decreased Abeta42 and tau pathologies by activating M1 mAChR, inhibiting GSK3beta, and modulating ADAM17/TACE and BACE1.

Conclusions:

  • AF267B is the first reported low molecular weight, CNS-penetrable mono-therapy targeting multiple hallmarks of Alzheimer's disease.
  • The M1 mAChR is a viable therapeutic target for AD, with selective agonists offering a promising treatment avenue.
  • Further clinical trials are warranted to determine the therapeutic potential of AF267B in Alzheimer's disease patients.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...